New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Hemispherx BioPharma, Inc (NYSEMKT:HEB), Camtek LTD (NASDAQ:CAMT), Aberdeen Asia-Pacific Income Fund, Inc (NYSEMKT:FAX), Templeton Global Income Fund (NYSE:GIM)
Hemispherx BioPharma, Inc (NYSEMKT:HEB) showed a volume of 1.17 million shares by the end of last trade whereas the average volume of the stock remained 1.66 million shares. The stock opened the session at $0.25 but then moved to $0.231. At that price, the stock showed a negative performance of -6.44%. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant)
Will HEB Get Buyers Even After The Recent Rally? Find Out Here
Camtek LTD (NASDAQ:CAMT) opened the session at $4.21 and closed the session at $4.16. The stock showed a positive performance of 3.23% in previous trading session. Camtek Ltd. (Camtek) designs, develops, manufactures and markets automated solutions dedicated for enhancing production processes and yield for the semiconductor manufacturing and packaging and the printed circuit board (PCB) and integrated circuit (IC) substrate industries. Camtek also designs, develops, manufactures and markets automated optical inspection (AOI), systems and related products.
For How Long CAMT will fight for Profitability? Read This Trend Analysis report
Aberdeen Asia-Pacific Income Fund, Inc (NYSEMKT:FAX) opened the session at $5.91 and closed the session at $5.90. The stock showed a negative performance of -0.34% in previous trading session. The beta of the stock remained 0.45. Aberdeen Asia-Pacific Income Fund, Inc. (the Fund) is a closed-end, non-diversified management investment company. The Fund’s principal investment objective is to seek current income. The Fund may also achieve incidental capital appreciation. Aberdeen Asia-Pacific Income Fund, Inc. invests in Australian and Asian debt securities. It invests at least 80% of its net assets plus the amount of any borrowings for investment purposes in Asian debt securities, Australian debt securities and New Zealand debt securities.
Why Should Investors Buy FAX After the Recent Fall? Just Go Here and Find Out
Templeton Global Income Fund (NYSE:GIM) the stock advanced 0.50% and finished the session at $8.05. Traded with volume of 1.62 million shares in the prior session and the average volume of the stock remained 613,481.00 shares. The beta of the stock remained 0.64. Templeton Global Income Fund (the Fund) is a closed-end investment company. The Fund seeks current income, with a secondary goal of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its net assets in income-producing securities, including debt securities of the United States and foreign issuers, including emerging markets.
Will GIM Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)